Anti-viral drug effective against coronavirus, study finds

Anti-viral drug effective against coronavirus, study finds

FILE PHOTO: A vial of redesivir
FILE PHOTO: An ampule of remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (COVID-19) continues. Ulrich Perrey/Pool via REUTERS/File Photo

WASHINGTON: Anti-viral drug remdesivir cuts recovery times in coronavirus patients, according to the full results of a trial published Friday (May 22) night, three weeks after America's top infectious diseases expert said the study showed the medication has "clear-cut" benefits.

Complete results from the research, which was carried out by US government agency the National Institute of Allergy and Infectious Diseases (NIAID), were published by leading medical periodical the New England Journal of Medicine.

READ: Ebola drug remdesivir used to treat COVID-19 patients in Singapore as part of clinical trials

The United States authorised the emergency use of remdesivir in hospitals on May 1, followed by Japan, while Europe is considering following suit.

The study found that remdesivir, injected intravenously daily for 10 days, accelerated the recovery of hospitalised COVID-19 patients compared to a placebo in clinical tests on just over a thousand patients across 10 countries.

On Apr 29, NIAID director Anthony Fauci, who has become the US government's trusted face on the coronavirus pandemic, said preliminary evidence indicated remdesivir had a "clear-cut, significant and positive effect in diminishing the time to recovery".

READ: US doctors call for remdesivir data to guide coronavirus treatment

The National Institutes of Health, of which the NIAID is a part, said Friday in a statement online that investigators found "remdesivir was most beneficial for hospitalised patients with severe disease who required supplemental oxygen".

But the authors of the trial wrote that the drug did not prevent all deaths.

"Given high mortality despite the use of remdesivir, it is clear that treatment with an anti-viral drug alone is not likely to be sufficient," they said.

About 7.1 per cent of patients given remdesivir in the trial group died within 14 days - compared with 11.9 per cent in the placebo group.

However, the result is just below the statistical reliability threshold, meaning it could be down to chance rather than the capability of the drug.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram

Source: AFP/aa

Bookmark